

## Saskatchewan Immunization Manual Amendments May 2022

**Instructions:** Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

### **Chapter 7 – Immunization of Special Populations**

- TOC ( second page)
  - Full algorithm title added to Appendix 7.4: High Dose Hepatitis B Immunization Algorithm - Renal, HIV, Congenital Immunodeficiency Deficiency Clients.
- Appendix 7.1 page 36
  - Foot note 2C now states: 1 dose for Pneu-C-13 naïve persons 5 years and older.

### **Chapter 10 Biological Products**

- Gardasil 9: updated product monograph as new indication for prevention of oropharyngeal cancers.
- Bexsero: updated product monograph with additional post-market AEFIs reported including: Hypotonic-hyporesponsive episode, syncope or vasovagal responses to injection, lymphadenopathy, injection site reactions like extensive swelling of the vaccinated limb, blisters at or around the injection site and/or a hard lump at the injection site (which may persist for more than one month) and allergic reactions (including anaphylactic reactions) have been reported as post-market events.

#### COVID-19 vaccines

- References to vaccine efficacy removed for most vaccines as this varies according to number of doses received.
- AstraZeneca Vaxzevria vaccine removed as no longer available in Canada.
- Janssen
  - Under Schedule: Last bullet now states: For booster dose details, refer to the Ministry of Health’s COVID – 19 Vaccine Contraindications and Precautions Background Document found in the [COVID-19 Immunization Manual](#).
  - Under Other Considerations: revised to the following:
    - In SK, individuals who are eligible for immunization (either first, second or subsequent doses) may be offered immunization as soon as their symptoms have improved.
    - However, Table 5 of the CIG COVID-19 chapter provides other interval guidelines: (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.2>)
    - Individuals presenting for immunization do not need to be tested for previous COVID-19 infection.
    - Immunization of individuals who may be currently infected with SARS-CoV-2 is not known to have a detrimental effect on the illness.
  - New reference: *Canadian Immunization Guide: COVID-19 Vaccines*: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>
- Moderna Spikevax 6+ years (Red cap)
  - Under Schedule: Last bullet now states: For booster dose details, refer to the Ministry of Health’s COVID – 19 Vaccine Contraindications and Precautions Background Document found in the [COVID-19 Immunization Manual](#).
  - Under Other Considerations: revised to the following:
    - In SK, individuals who are eligible for immunization (either first, second or subsequent doses) may be offered immunization as soon as their symptoms have improved.

## Saskatchewan Immunization Manual Amendments May 2022

- However, Table 5 of the CIG COVID-19 chapter provides other interval guidelines: (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.2>)
- Individuals presenting for immunization do not need to be tested for previous COVID-19 infection.
- Immunization of individuals who may be currently infected with SARS-CoV-2 is not known to have a detrimental effect on the illness.
- Under Storage and Handling, new bullet added to thawed unpunctured and thawed punctured to align with current work standard: **The duration of time an unpunctured vial is stored at room temperature is counted against the 24 hour stability period after puncture.**
- New reference: *Canadian Immunization Guide: COVID-19 Vaccines*: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>
- Novavax Nuvaxovid
  - Under Schedule: Last bullet now states: For booster dose details, refer to the Ministry of Health's COVID – 19 Vaccine Contraindications and Precautions Background Document found in the [COVID-19 Immunization Manual](#).
  - Under Other Considerations: revised to the following:
    - In SK, individuals who are eligible for immunization (either first, second or subsequent doses) may be offered immunization as soon as their symptoms have improved.
    - However, Table 5 of the CIG COVID-19 chapter provides other interval guidelines: (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.2>)
    - Individuals presenting for immunization do not need to be tested for previous COVID-19 infection.
    - Immunization of individuals who may be currently infected with SARS-CoV-2 is not known to have a detrimental effect on the illness.
  - New reference: *Canadian Immunization Guide: COVID-19 Vaccines*: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>
- Pfizer Comirnaty 12+ vaccine (purple cap and label):
  - Updated product monograph
  - Under Schedule: Last bullet now states: For booster dose details, refer to the Ministry of Health's COVID – 19 Vaccine Contraindications and Precautions Background Document found in the [COVID-19 Immunization Manual](#).
  - Under Other Considerations: revised to the following:
    - In SK, individuals who are eligible for immunization (either first, second or subsequent doses) may be offered immunization as soon as their symptoms have improved.
    - However, Table 5 of the CIG COVID-19 chapter provides other interval guidelines: (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.2>)
    - Individuals presenting for immunization do not need to be tested for previous COVID-19 infection.

## Saskatchewan Immunization Manual Amendments May 2022

- Immunization of individuals who may be currently infected with SARS-CoV-2 is not known to have a detrimental effect on the illness.
- Under Interchangeability: **Pfizer's 12+ Grey cap formulation (not yet available) is interchangeable with the 12+ years purple cap formulation.**
- New reference: *Canadian Immunization Guide: COVID-19 Vaccines*:  
<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>
- Pfizer Comirnaty 5-11 years vaccine (orange cap and label):
  - Updated product monograph
  - Under Other Considerations: revised to the following:
    - In SK, individuals who are eligible for immunization (either first, second or subsequent doses) may be offered immunization as soon as their symptoms have improved.
    - However, Table 5 of the CIG COVID-19 chapter provides other interval guidelines: (<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.2>)
    - Individuals presenting for immunization do not need to be tested for previous COVID-19 infection.
    - Immunization of individuals who may be currently infected with SARS-CoV-2 is not known to have a detrimental effect on the illness.
  - Under Storage and Handling second bullet: Upon moving the vaccine to a fridge between +2C to +8C, the updated expiry date must be written on the box and the vaccine should be used or discarded by the new expiry date (within 10 weeks, not exceeding the original expiry date [after 12 months from the date of manufacture printed on the vial and cartons]).